Cytori offered the securities in this transaction pursuant to an effective shelf registration statement.
The funds will be used for sales and marketing activities related to the commercialization of the Celution system and consumables as well as other related and complementary products, for ongoing clinical studies of the Celution system for breast reconstruction and cardiovascular disease, for ongoing R&D to support the company’s products and its pipeline development, and for general working capital.